Medication info

Losartan Plus Pro Tablet

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Ildong Pharmaceutical Co., Ltd.
Appearance
White to grayish oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 201001721 · Notified 2010.02.26

This product's status changed to Approval withdrawn on 2023.11.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect is observed approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the expected effect is not achieved with monotherapy. 1. Substitution therapy : The combination therapy of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy : Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy : Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia despite blood pressure control at this dose : Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. The clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg should then be monitored continuously. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment The usual dose should be administered if creatinine clearance is 30 mL/min or greater. Use of a loop diuretic rather than a thiazide-type drug is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. ○ Patients with hepatic impairment The initial dose of losartan potassium for patients with hepatic impairment requiring dose adjustment is 25 mg, which cannot be administered using this medicine. Therefore, use in these patients is not recommended.
Child dose
○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Ildong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used for hypertensive patients whose blood pressure is not sufficiently controlled with monotherapy. It helps lower blood pressure more effectively in conjunction with other treatments to prevent cardiovascular complications.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect is observed approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the expected effect is not achieved with monotherapy. 1. Substitution therapy : The combination therapy of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy : Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy : Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia despite blood pressure control at this dose : Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. The clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg should then be monitored continuously. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment The usual dose should be administered if creatinine clearance is 30 mL/min or greater. Use of a loop diuretic rather than a thiazide-type drug is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. ○ Patients with hepatic impairment The initial dose of losartan potassium for patients with hepatic impairment requiring dose adjustment is 25 mg, which cannot be administered using this medicine. Therefore, use in these patients is not recommended.

Child dose

○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately if pregnancy is confirmed. This medication is contraindicated or should be used with caution in individuals with certain conditions or allergies, particularly those with anuria, liver impairment, kidney impairment, hyperuricemia, gout, and hypotension. When taking this medication, blood pressure may drop too low or electrolyte imbalances may occur, so regular blood tests and adherence to medical advice are necessary. The hydrochlorothiazide component may make the skin sensitive to sunlight, so sun exposure should be avoided, and any skin abnormalities should be discussed with a physician immediately. This medication may interact with other drugs, so it's essential to inform a doctor or pharmacist of any other medications being taken. Dizziness or drowsiness may occur while on this medication, so caution is advised when driving or operating machinery. This drug should not be used in children and adolescents, and older adults should be cautious as adverse reactions may occur more frequently. Maintain adequate hydration while taking this medication; consult a physician immediately if symptoms such as vomiting or diarrhea occur. This medication should be stored out of reach of children and kept in its original container to maintain its quality.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • low back pain
  • dizziness
Show 128 more
  • cough
  • sinusitis
  • upper respiratory tract infection
  • rash
  • angioedema
  • desquamation
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina pectoris
  • arrhythmia
  • cerebrovascular accident
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscular rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • hypersensitivity
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremors
  • dyspnea
  • epistaxis
  • nasal congestion
  • throat discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • phototoxic reactions
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • vision impairment
  • taste abnormalities
  • tinnitus
  • erectile dysfunction
  • nocturia
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle spasms
  • restlessness
  • renal failure
  • renal dysfunction
  • interstitial nephritis
  • Stevens-Johnson syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute closed-angle glaucoma
  • hypotension
  • tachycardia
  • angioedema
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • erythematous rash
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container that can block light, preferably at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness.

Appearance and packaging

Appearance

White to grayish oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.